Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Oral Solution in Dravet Syndrome
NCT02318563Phase 3Withdrawn
- Sponsor
- Insys Therapeutics
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing Cannabidiol Oral Solution with Placebo (2 arms). Primary endpoint: Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components at 12 weeks. Planned start Dec 2017; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT02318563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318563.